Ar
Non verificato

Arcus Biosciences

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute
04/11/2026
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
1.00
02/11/2026
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
1.00
22/10/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Mercato azionario
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
1.00
21/10/2026
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Scienza
Farmaceutica
Mercato azionario
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
1.00
20/10/2026
Multimedialità
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Web e Social Network
Telefonia e Varie
Industria
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
1.00
09/10/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Arcus Biosciences Announces New Employment Inducement Grants
1.00
24/09/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Arcus Biosciences Announces New Employment Inducement Grants
1.00
22/09/2026
Web e Social Network
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
1.00
09/09/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Arcus Biosciences Announces New Employment Inducement Grants
1.00
26/08/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0